

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

July 9, 2018
Date of Report (date of earliest event reported)



Cutera, Inc.

(Exact name of Registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation)

000-50644
(Commission File Number)

77-0492262
(IRS Employer
Identification No.)

3240 Bayshore Blvd.
Brisbane, California 94005
(Address of principal executive offices)

(415) 657-5500
(Registrant's telephone number, including area code)

N/A
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

(c) Appointment of Chief Operating Officer

On July 9, 2018, Cutera, Inc. (the “Company” or “Cutera”) announced that R. Jason Richey, age 44, joins the Company as Chief Operating Officer, effective July 9, 2018, for a term lasting until his earlier death, disability, retirement or removal. Mr. Richey assumes the role as an officer of the Company. Prior to joining Cutera, Mr. Richey served as President of North America for LivaNova, PLC, a global medical device manufacturer headquartered in London. Mr. Richey joined LivaNova from Cyberonics, Inc. upon the creation of LivaNova through a merger of Cyberonics and Sorin S.p.A. in October 2015. Together, Mr. Richey spent 17 years in various commercial and operational roles of increasing responsibility at Cyberonics and LivaNova. Prior to that, Mr. Richey held roles at B Braun Medical.

There is no arrangement or understanding between Mr. Richey and any other persons pursuant to which Mr. Richey was selected as an officer. Neither Mr. Richey nor any related person of Mr. Richey has a direct or indirect material interest in any existing or currently proposed transaction to which the Company is or may become a party. Mr. Richey does not have a family relationship with any of the executive officers or directors of the Company.

In connection with his appointment, Mr. Richey will receive (1) an annual base salary of \$505,000, (2) a potential annual incentive bonus target equal to 75% of his annual base salary pursuant to the Company’s annual management bonus plan in place in any given year, (3) a one-time relocation assistance payment of \$100,000, provided that Mr. Richey completes his relocation to the San Francisco Bay Area by March 2019. This payment will be forgiven over a 24 month period in equal monthly increments with any outstanding amounts to be reimbursed by Mr. Richey should he voluntarily terminate his employment without cause; and (4) other such benefits as are generally made available to Brisbane-based Cutera employees.

In addition, the Company also agreed to recommend to the Compensation Committee of the Board of Directors of the Company an inducement award of restricted stock units (“RSUs”) with a grant date fair value of \$2,418,956 vesting annually over a four-year period commencing from the date of hire, subject to Mr. Richey continuing to provide service to the Company through such vesting date.

In connection with Mr. Richey’s appointment, the Company intends to enter into a Change of Control and Severance Agreement with Mr. Richey (the “COC Agreement”) on substantially similar terms to agreements entered into between the Company and the Company’s other named executive officers. The COC Agreement will provide that if Mr. Richey’s employment with the Company is terminated by the Company without “cause” (as defined in the COC Agreement) or by Mr. Richey for “good reason” not in connection with a change of control of the Company (commonly referred to as “single trigger”), Mr. Richey will receive, subject to signing a release of claims in favor of the Company, 100% of his base salary, 100% of his actual bonus paid in the prior fiscal year, and 12 months of COBRA reimbursement. The COC Agreement will also provide that if Mr. Richey’s employment with the Company is terminated by the Company without “cause” or by Mr. Richey for “good reason” and such termination occurs in connection with a change of control (commonly referred to as “double trigger”), Mr. Richey will receive, subject to signing a release of claims in favor of the Company, the same benefits as following a single-trigger termination, as well as the automatic vesting in full of all outstanding and unvested equity awards that solely vest on a time-basis held by Mr. Richey as of the date of the change of control.

Item 7.01. Regulation FD Disclosure.

On July 9, 2018, the Company issued a press release announcing Mr. Richey’s appointment as Chief Operating Officer. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Limitation on Incorporation by Reference:

In accordance with general instruction B.2 of Form 8-K, the information in this Item 7.01, including exhibits incorporated by reference, is furnished pursuant to Item 7.01 and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section.

Item 9.01. Operating Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	<u>Press Release issued by Cutera, Inc. dated July 9, 2018.</u>

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Cutera, Inc.

Date: July 9, 2018

By: /s/ Darren W. Alch
Name: Darren W. Alch
Title: Vice president, General Counsel & Corporate Secretary



FOR IMMEDIATE RELEASE

Cutera, Inc.
Matthew Scalo
VP, Investor Relations and Corporate Development
415-657-5500
mscalo@cutera.com

Cutera Announces Appointment of Jason Richey as Chief Operating Officer

[BRISBANE, Calif., July 9, 2018] -- CUTERA, INC., (Nasdaq: CUTR) ("Cutera" or the "Company") a leading provider of laser, light and other energy-based aesthetic systems for practitioners worldwide, announced today the appointment of Mr. Jason Richey to the newly created position of Chief Operating Officer ("COO").

Immediately prior to joining Cutera, Mr. Richey served as President of North America for LivaNova, PLC, a \$5 billion global medical device manufacturer headquartered in London, with a presence in more than 100 countries worldwide. Mr. Richey joined LivaNova (created through the merger of Cyberonics, Inc. and Sorin S.p.A. in October 2015) from Cyberonics, Inc. where he spent 17 years. At Cyberonics, among other roles, Mr. Richey also served as the Vice President and General Manager of the Company's International business based in Brussels, Belgium. In this role, Mr. Richey led a turnaround of Cyberonics' international business that saw substantial growth, while simultaneously driving significant profitability to the corporation. In addition to LivaNova and Cyberonics, Mr. Richey began his medical device career at B Braun Medical. Mr. Richey holds a Bachelor of Arts degree in Biology from the Indiana University.

"We're delighted to welcome Jason to Cutera as a member of our Executive Leadership Team," said James Reinstein, Cutera's President and Chief Executive Officer. "Jason comes to us with deep operational expertise in the medical device industry, extensive experience managing international commercial teams, as well as broad sales, marketing and regulatory acumen to manage our fast growing global business. Having worked with Jason at Cyberonics, I am confident he will drive overall performance and make a significant impact on our entire organization," said Mr. Reinstein.

"I am thrilled to join James and this exceptional team at Cutera," said Mr. Richey. "I see tremendous opportunities ahead and look forward to applying my knowledge and experience to contribute to even greater success and shareholder value."

For more information about Cutera and its products, visit www.Cutera.com.

About Cutera, Inc.

Brisbane, California-based Cutera is a leading provider of laser and other energy-based aesthetic systems for practitioners worldwide. Since 1998, Cutera has been developing innovative, easy-to-use products that enable physicians and other qualified practitioners to offer safe and effective aesthetic treatments to their patients. For more information, call 1-888-4CUTERA or visit www.cutera.com.